Genetic deficiency for CETP increases plasma HDL‐cholesterol (C) and decreases cardiovascular events.11 This has led to the development of CETP inhibition as a potential strategy for the treatment of cardiovascular disease. The gene discussed is CETP; the disease is cardiovascular disorder.